The researchers came to a conclusion that such an administration of cholecalciferol can render ALA-PDT to be a safe neo-adjuvant and it could be used for cancer pretreatment before PDT for human patients [283] Bhuvaneswari et al. evaluated the efficacy of PDT in combination with an epidermal growth factor receptor (EGFR) inhibitor, nimotuzumab, in oral cancer cell lines and an OSCC xenograft tumor model. The gene discussed is EGFR; the disease is lip and oral cavity carcinoma.